Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup round for I/O work
→ Celgene $CELG and its partners at bluebird bio $BLUE can add boasting rights to the FDA’s breakthrough drug program for their closely watched work …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.